Published in J Cell Physiol on October 01, 2010
An update on molecular genetics of Alkaptonuria (AKU). J Inherit Metab Dis (2011) 1.18
Alkaptonuria is a novel human secondary amyloidogenic disease. Biochim Biophys Acta (2012) 1.09
Homogentisate 1,2 dioxygenase is expressed in human osteoarticular cells: implications in alkaptonuria. J Cell Physiol (2012) 1.04
Biochemical and proteomic characterization of alkaptonuric chondrocytes. J Cell Physiol (2012) 0.99
Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria. Rheumatology (Oxford) (2013) 0.98
Redox-proteomics of the effects of homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis. J Inherit Metab Dis (2011) 0.96
Amyloidosis in alkaptonuria. J Inherit Metab Dis (2015) 0.84
Amyloidosis, inflammation, and oxidative stress in the heart of an alkaptonuric patient. Mediators Inflamm (2014) 0.83
Secondary amyloidosis in an alkaptonuric aortic valve. Int J Cardiol (2014) 0.79
The Pigment in Alkaptonuria Relationship to Melanin and Other Coloured Substances: A Review of Metabolism, Composition and Chemical Analysis. JIMD Rep (2015) 0.79
Chondroptosis in alkaptonuric cartilage. J Cell Physiol (2015) 0.78
Homogentisate 1,2 dioxygenase is expressed in brain: implications in alkaptonuria. J Inherit Metab Dis (2015) 0.76
Diagnosis of secondary amyloidosis in alkaptonuria. Diagn Pathol (2014) 0.75
Angiogenesis in alkaptonuria. J Inherit Metab Dis (2016) 0.75
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) (2003) 4.00
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum (2002) 3.96
Colchicine myopathy and neuromyopathy: two cases with different characteristics. J Clin Rheumatol (2010) 2.17
Micro-computed tomography with iodine staining resolves the arrangement of muscle fibres. J Biomech (2010) 2.02
Statins and the joint: multiple targets for a global protection? Semin Arthritis Rheum (2010) 1.97
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum (2004) 1.89
Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases. Arthritis Rheum (2004) 1.59
Serum amyloid-A in Behçet's disease. Clin Rheumatol (2014) 1.47
Guillain-Barré syndrome following adalimumab treatment. Clin Exp Rheumatol (2012) 1.41
Phytothermotherapy in osteoarthritis: a randomized controlled clinical trial. J Altern Complement Med (2011) 1.38
miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Hum Immunol (2009) 1.34
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol (2007) 1.34
Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken) (2013) 1.29
Development of an in vitro model to investigate joint ochronosis in alkaptonuria. Rheumatology (Oxford) (2010) 1.28
Recent advances in management of alkaptonuria (invited review; best practice article). J Clin Pathol (2013) 1.27
Autoantibody-mediated cardiac arrhythmias: mechanisms and clinical implications. Basic Res Cardiol (2007) 1.26
Connective tissue diseases and cardiac rhythm disorders: an overview. Autoimmun Rev (2005) 1.25
Alkaptonuria, ochronosis, and ochronotic arthropathy. Semin Arthritis Rheum (2004) 1.24
Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum (2006) 1.21
Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies. Cell Biochem Funct (2010) 1.20
Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone. Ann Rheum Dis (2013) 1.18
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis (2006) 1.16
Mechanisms of action of spa therapies in rheumatic diseases: what scientific evidence is there? Rheumatol Int (2010) 1.14
Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther (2009) 1.12
Evaluation of anti-oxidant treatments in an in vitro model of alkaptonuric ochronosis. Rheumatology (Oxford) (2010) 1.11
Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun Rev (2007) 1.11
Reactivity to superficial and deep stimuli in patients with chronic musculoskeletal pain. Pain (2002) 1.11
Extragastric manifestations of Helicobacter pylori infection. Helicobacter (2010) 1.11
Negative Helicobacter pylori status is associated with poor prognosis in patients with gastric cancer. Cancer (2009) 1.10
Alkaptonuria is a novel human secondary amyloidogenic disease. Biochim Biophys Acta (2012) 1.09
Biochemical investigation of the effects of human platelet releasates on human articular chondrocytes. J Cell Biochem (2009) 1.09
Cardiovascular manifestations of Alkaptonuria. J Inherit Metab Dis (2011) 1.08
Antimicrobial activity against Helicobacter pylori strains and antioxidant properties of blackberry leaves (Rubus ulmifolius) and isolated compounds. Int J Antimicrob Agents (2009) 1.06
Human keratinocytes release ATP and utilize three mechanisms for nucleotide interconversion at the cell surface. J Biol Chem (2005) 1.05
Homogentisate 1,2 dioxygenase is expressed in human osteoarticular cells: implications in alkaptonuria. J Cell Physiol (2012) 1.04
Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun Rev (2012) 1.03
Proteomic and redox-proteomic evaluation of homogentisic acid and ascorbic acid effects on human articular chondrocytes. J Cell Biochem (2010) 1.03
Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet Disord (2014) 1.03
Evidence for synovitis in active polymyalgia rheumatica: sonographic study in a large series of patients. J Rheumatol (2002) 1.02
A "new" technique for the diagnosis of chondrocalcinosis of the knee: sensitivity and specificity of high-frequency ultrasonography. Ann Rheum Dis (2007) 1.02
Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol (2012) 1.02
Polymorphisms in the P2X7 receptor gene are associated with low lumbar spine bone mineral density and accelerated bone loss in post-menopausal women. Eur J Hum Genet (2012) 1.02
Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol (2008) 1.00
Biochemical and proteomic characterization of alkaptonuric chondrocytes. J Cell Physiol (2012) 0.99
Vascular endothelial growth factor-D activates VEGFR-3 expressed in osteoblasts inducing their differentiation. J Biol Chem (2006) 0.99
Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria. Rheumatology (Oxford) (2013) 0.98
A proteomic study on human osteoblastic cells proliferation and differentiation. Proteomics (2006) 0.98
Ultrastructural examination of tissue in a patient with alkaptonuric arthropathy reveals a distinct pattern of binding of ochronotic pigment. Rheumatology (Oxford) (2010) 0.98
Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. Clin Rheumatol (2010) 0.98
Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clin Transl Allergy (2012) 0.97
Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: a two-dimensional electrophoretic study. Electrophoresis (2002) 0.97
Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage (2004) 0.97
Proteomic response to physiological fermentation stresses in a wild-type wine strain of Saccharomyces cerevisiae. Biochem J (2003) 0.96
Redox-proteomics of the effects of homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis. J Inherit Metab Dis (2011) 0.96
Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int (2009) 0.95